Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Oct 7, 2013; 19(37): 6165-6169
Published online Oct 7, 2013. doi: 10.3748/wjg.v19.i37.6165
HER2 therapies and gastric cancer: A step forward
Ramon Andrade de Mello, Andrea Marin Marques, António Araújo
Ramon Andrade de Mello, António Araújo, Department of Medical Oncology, Gastrointestinal Unit, Portuguese Oncology Institute, 4200-072 Porto, Portugal
Ramon Andrade de Mello, Department of Medicine, FMUP-Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal
Andrea Marin Marques, Centro Hospitalar Médio Ave, Unidade Santo Tirso, 4780-371 Porto, Portugal
Author contributions: All authors contributed as the same for the manuscript preparation and design.
Supported by Grants from Janssen and Merck Serono to de Mello RA
Correspondence to: Ramon Andrade de Mello, MD, PhD, Department of Medical Oncology, Gastrointestinal Unit, Portuguese Oncology Institute, Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.
Telephone: +351-225-084000-7323 Fax: +351-225-084010
Received: June 3, 2013
Revised: July 25, 2013
Accepted: August 12, 2013
Published online: October 7, 2013
Core Tip

Core tip: Approaches for treatment advanced gastric cancer are object of interesting debates toward scientific community worldwide over the last 20 years. Chemotherapy based on platinum and fluoropirimidine agents remained up to now the standard of care for those patients, otherwise triplet therapy either an anthracycline or taxane may be considered. Herein we provide an additional discussion regarding the role of biologic agents, such as trastuzumab and novel therapies for improve survival in this field.